FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
about
Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now?The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment ResponseMagnetic particle imaging (MPI) for NMR and MRI researchersTailoring the magnetic and pharmacokinetic properties of iron oxide magnetic particle imaging tracersIntravenous iron therapy: how far have we come?Engineered nanomaterial exposure and the risk of allergic diseaseWhite Paper on P4 Concepts for Pediatric ImagingNanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.Linearity and shift invariance for quantitative magnetic particle imagingDesign of superparamagnetic nanoparticles for magnetic particle imaging (MPI).Imaging and drug delivery using theranostic nanoparticlesMagnetic Resonance Imaging of Iron Oxide-Labeled Human Embryonic Stem Cell-Derived Cardiac ProgenitorsNon-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle.MR Imaging of Stem Cell Transplants in Arthritic Joints.The pharmacokinetics and pharmacodynamics of iron preparations.Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.IRON fMRI measurements of CBV and implications for BOLD signalNanopharmaceuticals (part 1): products on the market.Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapyNoninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients.New findings about iron oxide nanoparticles and their different effects on murine primary brain cells.MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticlesPhysicochemical characterization of nebulized superparamagnetic iron oxide nanoparticles (SPIONs).Characterizing the interactions of organic nanoparticles with renal epithelial cells in vivo.Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol.Magnetic particle imaging with tailored iron oxide nanoparticle tracersLabeling stem cells with ferumoxytol, an FDA-approved iron oxide nanoparticle.Imaging Tumor Necrosis with FerumoxytolIron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.An x-space magnetic particle imaging scannerEffects of ferumoxytol on quantitative PET measurements in simultaneous PET/MR whole-body imaging: a pilot study in a baboon model.The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease.Glyconanomaterials: Emerging applications in biomedical researchGlyconanomaterials for biosensing applications.Magnetic Nanoparticles: Material Engineering and Emerging Applications in Lithography and Biomedicine.In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticlesIntravenous ferric carboxymaltose for the treatment of iron deficiency anemia.Short- and Long-Term Effects of Prenatal Exposure to Iron Oxide Nanoparticles: Influence of Surface Charge and Dose on Developmental and Reproductive Toxicity.Low drive field amplitude for improved image resolution in magnetic particle imaging.Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study.
P2860
Q26739877-268AB8F9-0688-4F05-906F-C34EF1C51205Q26773129-8A91E52C-58BE-409D-9C65-B4791DB3A3BCQ26827983-95005EBA-6476-4944-A817-90403C027F26Q27023739-A40C334A-7C65-457B-AA56-298179D5635DQ28276678-44B32A2F-0C40-47EB-B342-4FDE88266102Q28389510-26618D0A-2140-48B6-B261-E57D7B9534A2Q30357689-63BD60DC-E99B-4BC4-8C30-67EE712D4EF1Q30387307-77DD69B5-60D6-4099-8D34-688A230206C1Q30446824-712F9F8D-8173-4522-B0B6-BB3229313826Q30448145-419E787D-7352-4940-9D2D-CD57B4C04FC6Q30449480-78CEFF6F-7EAD-472A-98AE-0A7FD5E2C66CQ30696266-21E7FF09-6C13-4E87-B6D7-E5E9012C861FQ33841759-FB78D447-7ED4-4E75-A6C4-E41CA16B163AQ33949771-0278FA79-434A-4264-93B3-B79A2528E9DBQ34039226-9AF06058-336F-4274-8643-C24807B896B9Q34085240-A16D20AF-064A-4FC7-B7C9-1E74323519C6Q34142546-6CBEAF71-693D-4B32-B4BA-CF3B55E96D55Q34230175-4D3CFEF9-B159-452E-81C1-D5A8A45DEFB7Q34821739-0E570D85-7031-4F97-A7C6-2B794861BE17Q35128879-5AE899F2-DC2F-4D82-ACF6-58D267825D1EQ35191259-1AB95C59-FEBE-41F1-8F1B-62ACAB2010CAQ35196287-B4F2F863-83AD-4113-B6E2-51BB41CC528EQ35200143-FD8879EF-7AA7-47BB-8158-E06E0B97DBDFQ35554673-67FE658E-664D-42F9-A71B-52BBE549F410Q35574227-DF419EF4-062B-4237-981C-D02316B0E06CQ35597949-3F203F2C-9B17-4D99-9408-A5CF785FB64EQ35841583-17A12F2F-D656-49A3-A29A-562125ADF5DDQ35841636-5C5980A2-E047-4333-8C91-526F2FE6C2F4Q35857178-819E87F0-41E2-422F-9ACA-5F15A6AD51E7Q35874632-32F4E0F3-49D5-4793-A6E0-3C76F6D576A3Q35981341-B8896FED-EB4C-465D-B5FC-42FB678B247AQ36073903-C9C83512-1FAE-493D-AC42-80729C5E5A38Q36197131-7658DB9E-6306-4D5A-B15E-086F5873C27BQ36260313-8A8E4805-3945-465B-BE47-7511570ECE47Q36283461-D59B90CF-470C-47B3-ABBB-EEE1A1F7F162Q36289257-E7A178E8-FD22-46B8-86BD-38D11554D2A1Q36371086-D7D9D4DF-012E-4FA7-A224-FA2115829F5DQ36404343-CB5AE795-D3FF-4203-BB11-C6821A9CF214Q36421586-5553E630-1689-4ADF-8176-A96DAC5582CDQ36428997-7EA9F449-CB79-4DD7-8E5A-690F5BE89FD1
P2860
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
FDA report: Ferumoxytol for in ...... s with chronic kidney disease.
@en
FDA report: Ferumoxytol for in ...... s with chronic kidney disease.
@nl
type
label
FDA report: Ferumoxytol for in ...... s with chronic kidney disease.
@en
FDA report: Ferumoxytol for in ...... s with chronic kidney disease.
@nl
prefLabel
FDA report: Ferumoxytol for in ...... s with chronic kidney disease.
@en
FDA report: Ferumoxytol for in ...... s with chronic kidney disease.
@nl
P2093
P356
P1476
FDA report: Ferumoxytol for in ...... s with chronic kidney disease.
@en
P2093
Dwaine Rieves
Martin H Cohen
Richard Pazdur
P304
P356
10.1002/AJH.21656
P577
2010-05-01T00:00:00Z